<!DOCTYPE html><html lang="en" ><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta name="theme-color" media="(prefers-color-scheme: light)" content="#f7f7f7"><meta name="theme-color" media="(prefers-color-scheme: dark)" content="#1b1b1e"><meta name="apple-mobile-web-app-capable" content="yes"><meta name="apple-mobile-web-app-status-bar-style" content="black-translucent"><meta name="viewport" content="width=device-width, user-scalable=no initial-scale=1, shrink-to-fit=no, viewport-fit=cover" ><meta name="generator" content="Jekyll v4.3.2" /><meta property="og:title" content="MDCT Necrosis Quantification in the Assessment of Hepatocellular Carcinoma Response to Yttrium 90 Radioembolization Therapy" /><meta property="og:locale" content="en" /><meta name="description" content="Rationale and Objectives" /><meta property="og:description" content="Rationale and Objectives" /><link rel="canonical" href="https://clinicaltree.github.io/posts/mdct-necrosis-quantification-in-the-assessment-of-hepatocellular-carcinoma-response-to-yttrium-90-ra/" /><meta property="og:url" content="https://clinicaltree.github.io/posts/mdct-necrosis-quantification-in-the-assessment-of-hepatocellular-carcinoma-response-to-yttrium-90-ra/" /><meta property="og:site_name" content="Radiology Tree" /><meta property="og:type" content="article" /><meta property="article:published_time" content="2011-12-31T17:00:00+00:00" /><meta name="twitter:card" content="summary" /><meta property="twitter:title" content="MDCT Necrosis Quantification in the Assessment of Hepatocellular Carcinoma Response to Yttrium 90 Radioembolization Therapy" /><meta name="twitter:site" content="@twitter_username" /><meta name="google-site-verification" content="RFHVRgQqK0eGjftEMCTDhsDrR8cJ_ZYcfCX52gXW8KM" /> <script type="application/ld+json"> {"@context":"https://schema.org","@type":"BlogPosting","dateModified":"2023-04-10T02:43:55+00:00","datePublished":"2011-12-31T17:00:00+00:00","description":"Rationale and Objectives","headline":"MDCT Necrosis Quantification in the Assessment of Hepatocellular Carcinoma Response to Yttrium 90 Radioembolization Therapy","mainEntityOfPage":{"@type":"WebPage","@id":"https://clinicaltree.github.io/posts/mdct-necrosis-quantification-in-the-assessment-of-hepatocellular-carcinoma-response-to-yttrium-90-ra/"},"url":"https://clinicaltree.github.io/posts/mdct-necrosis-quantification-in-the-assessment-of-hepatocellular-carcinoma-response-to-yttrium-90-ra/"}</script><title>MDCT Necrosis Quantification in the Assessment of Hepatocellular Carcinoma Response to Yttrium 90 Radioembolization Therapy | Radiology Tree</title><link rel="apple-touch-icon" sizes="180x180" href="/assets/img/favicons/apple-touch-icon.png"><link rel="icon" type="image/png" sizes="32x32" href="/assets/img/favicons/favicon-32x32.png"><link rel="icon" type="image/png" sizes="16x16" href="/assets/img/favicons/favicon-16x16.png"><link rel="manifest" href="/assets/img/favicons/site.webmanifest"><link rel="shortcut icon" href="/assets/img/favicons/favicon.ico"><meta name="apple-mobile-web-app-title" content="Radiology Tree"><meta name="application-name" content="Radiology Tree"><meta name="msapplication-TileColor" content="#da532c"><meta name="msapplication-config" content="/assets/img/favicons/browserconfig.xml"><meta name="theme-color" content="#ffffff"><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://fonts.gstatic.com" crossorigin><link rel="dns-prefetch" href="https://fonts.gstatic.com" crossorigin><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://cdn.jsdelivr.net" ><link rel="dns-prefetch" href="https://cdn.jsdelivr.net" ><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Lato&family=Source+Sans+Pro:wght@400;600;700;900&display=swap"><link rel="preconnect" href="https://www.google-analytics.com" crossorigin="use-credentials"><link rel="dns-prefetch" href="https://www.google-analytics.com"><link rel="preconnect" href="https://www.googletagmanager.com" crossorigin="anonymous"><link rel="dns-prefetch" href="https://www.googletagmanager.com"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/css/bootstrap.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/@fortawesome/fontawesome-free@6.2.1/css/all.min.css"><link rel="stylesheet" href="/assets/css/style.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/magnific-popup@1.1.0/dist/magnific-popup.min.css"> <script src="https://cdn.jsdelivr.net/npm/jquery@3.6.1/dist/jquery.min.js"></script> <script type="text/javascript"> class ModeToggle { static get MODE_KEY() { return "mode"; } static get MODE_ATTR() { return "data-mode"; } static get DARK_MODE() { return "dark"; } static get LIGHT_MODE() { return "light"; } static get ID() { return "mode-toggle"; } constructor() { if (this.hasMode) { if (this.isDarkMode) { if (!this.isSysDarkPrefer) { this.setDark(); } } else { if (this.isSysDarkPrefer) { this.setLight(); } } } let self = this; /* always follow the system prefers */ this.sysDarkPrefers.addEventListener('change', () => { if (self.hasMode) { if (self.isDarkMode) { if (!self.isSysDarkPrefer) { self.setDark(); } } else { if (self.isSysDarkPrefer) { self.setLight(); } } self.clearMode(); } self.notify(); }); } /* constructor() */ get sysDarkPrefers() { return window.matchMedia("(prefers-color-scheme: dark)"); } get isSysDarkPrefer() { return this.sysDarkPrefers.matches; } get isDarkMode() { return this.mode === ModeToggle.DARK_MODE; } get isLightMode() { return this.mode === ModeToggle.LIGHT_MODE; } get hasMode() { return this.mode != null; } get mode() { return sessionStorage.getItem(ModeToggle.MODE_KEY); } /* get the current mode on screen */ get modeStatus() { if (this.isDarkMode || (!this.hasMode && this.isSysDarkPrefer)) { return ModeToggle.DARK_MODE; } else { return ModeToggle.LIGHT_MODE; } } setDark() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.DARK_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.DARK_MODE); } setLight() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.LIGHT_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.LIGHT_MODE); } clearMode() { $('html').removeAttr(ModeToggle.MODE_ATTR); sessionStorage.removeItem(ModeToggle.MODE_KEY); } /* Notify another plugins that the theme mode has changed */ notify() { window.postMessage({ direction: ModeToggle.ID, message: this.modeStatus }, "*"); } flipMode() { if (this.hasMode) { if (this.isSysDarkPrefer) { if (this.isLightMode) { this.clearMode(); } else { this.setLight(); } } else { if (this.isDarkMode) { this.clearMode(); } else { this.setDark(); } } } else { if (this.isSysDarkPrefer) { this.setLight(); } else { this.setDark(); } } this.notify(); } /* flipMode() */ } /* ModeToggle */ const modeToggle = new ModeToggle(); </script><body data-topbar-visible="true"><div id="sidebar" class="d-flex flex-column align-items-end"><div class="profile-wrapper text-center"><div id="avatar"> <a href="/" class="mx-auto"> <img src="https://storage.googleapis.com/clinicalpub.com/images/favicon.png" alt="avatar" onerror="this.style.display='none'"> </a></div><div class="site-title"> <a href="/">Radiology Tree</a></div><div class="site-subtitle font-italic">Update every day the best and the lastest articles, books, journals, clinical cases, videos, images... for radiologist</div></div><ul class="w-100"><li class="nav-item"> <a href="/" class="nav-link"> <i class="fa-fw fas fa-home ml-xl-3 mr-xl-3 unloaded"></i> <span>HOME</span> </a><li class="nav-item"> <a href="/categories/" class="nav-link"> <i class="fa-fw fas fa-stream ml-xl-3 mr-xl-3 unloaded"></i> <span>CATEGORIES</span> </a><li class="nav-item"> <a href="/tags/" class="nav-link"> <i class="fa-fw fas fa-tag ml-xl-3 mr-xl-3 unloaded"></i> <span>TAGS</span> </a><li class="nav-item"> <a href="/archives/" class="nav-link"> <i class="fa-fw fas fa-archive ml-xl-3 mr-xl-3 unloaded"></i> <span>ARCHIVES</span> </a><li class="nav-item"> <a href="/about/" class="nav-link"> <i class="fa-fw fas fa-info-circle ml-xl-3 mr-xl-3 unloaded"></i> <span>ABOUT</span> </a></ul><div class="sidebar-bottom mt-auto d-flex flex-wrap justify-content-center align-items-center"> <button class="mode-toggle btn" aria-label="Switch Mode"> <i class="fas fa-adjust"></i> </button> <span class="icon-border"></span> <a href="https://github.com/clinicaltree" aria-label="github" target="_blank" rel="noopener noreferrer"> <i class="fab fa-github"></i> </a> <a href="https://twitter.com/twitter_username" aria-label="twitter" target="_blank" rel="noopener noreferrer"> <i class="fab fa-twitter"></i> </a> <a href="javascript:location.href = 'mailto:' + ['clinicalpub.team','gmail.com'].join('@')" aria-label="email" > <i class="fas fa-envelope"></i> </a> <a href="/feed.xml" aria-label="rss" > <i class="fas fa-rss"></i> </a></div></div><div id="topbar-wrapper"><div id="topbar" class="container d-flex align-items-center justify-content-between h-100 pl-3 pr-3 pl-md-4 pr-md-4"> <span id="breadcrumb"> <span> <a href="/"> Home </a> </span> <span>MDCT Necrosis Quantification in the Assessment of Hepatocellular Carcinoma Response to Yttrium 90 Radioembolization Therapy</span> </span> <i id="sidebar-trigger" class="fas fa-bars fa-fw"></i><div id="topbar-title"> Post</div><i id="search-trigger" class="fas fa-search fa-fw"></i> <span id="search-wrapper" class="align-items-center"> <i class="fas fa-search fa-fw"></i> <input class="form-control" id="search-input" type="search" aria-label="search" autocomplete="off" placeholder="Search..."> </span> <span id="search-cancel" >Cancel</span></div></div><div id="main-wrapper" class="d-flex justify-content-center"><div id="main" class="container pl-xl-4 pr-xl-4"><div class="row"><div id="core-wrapper" class="col-12 col-lg-11 col-xl-9 pr-xl-4"><div class="post pl-1 pr-1 pl-md-2 pr-md-2"><h1 data-toc-skip>MDCT Necrosis Quantification in the Assessment of Hepatocellular Carcinoma Response to Yttrium 90 Radioembolization Therapy</h1><div class="post-meta text-muted"> <span> Posted <em class="" data-ts="1325350800" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Dec 31, 2011 </em> </span> <span> Updated <em class="" data-ts="1681094635" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Apr 10, 2023 </em> </span><div class="d-flex justify-content-between"> <span> By <em> <a href="">Mauricio Stanzione Galizia MD</a> </em>, <em> <a href="">Hüseyin Gürkan Töre MD</a> </em>, <em> <a href="">Hamid Chalian MD</a> </em>, <em> <a href="">Robert McCarthy MD</a> </em>, <em> <a href="">Riad Salem MD</a> </em>, <em> <a href="">Vahid Yaghmai MD</a> </em> </span><div> <span class="readtime" data-toggle="tooltip" data-placement="bottom" title="2277 words"> <em>12 min</em> read</span></div></div></div><div class="post-content"><h2 id="rationale-and-objectives"><span class="mr-2">Rationale and Objectives</span><a href="#rationale-and-objectives" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>The purpose of this study is to evaluate the reproducibility and agreement of tumor necrosis quantification performed by two-dimensional and volumetric methods in a cohort of patients with hepatocellular carcinoma (HCC) treated with yttrium-90 ( 90 Y) radioembolization.</p><h2 id="materials-and-methods"><span class="mr-2">Materials and Methods</span><a href="#materials-and-methods" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Twenty-nine consecutive patients (21 men, 8 women; mean age 66.6 years; age range, 44–90 years) with HCC treated with 90 Y radioembolization that underwent liver multidetector computed tomography (MDCT) were included. Two independent radiologists evaluated the necrosis proportion of the lesions with two-dimensional (2D) measurements according to the European Association for the Study of the Liver guidelines, and with a volumetric method using a voxel-by-voxel analysis. Interobserver reproducibility for each method was assessed by using within-subject coefficients of variation (WSCV), intraclass correlation coefficients (ICC), and Lin’s concordance correlation coefficients (LCC). Agreement between both methods was assessed by using the Bland-Altman plot and the paired <em>t</em> -test.</p><h2 id="results"><span class="mr-2">Results</span><a href="#results" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>The volumetric method was more reproducible (WSCV = 27.8%; ICC = 0.914; LCC = 0.909) than the 2D (WSCV = 43.8%; ICC = 0.723; LCC = 0.841). There was a significant difference in the mean calculated necrosis proportions based on 2D and volumetric methods ( <em>P</em> = .0129).</p><h2 id="conclusion"><span class="mr-2">Conclusion</span><a href="#conclusion" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Voxel-by-voxel quantification of HCC necrosis is a more reproducible method than 2D analysis.</p><p>Hepatocellular carcinoma (HCC) is potentially curable by surgical resection or transplantation , but usually only 15%–25% of the patients are candidates for surgery . Because most chemotherapeutic agents have marginal antitumoral effects , a significant portion of patients are treated with target-directed therapies, such as radiofrequency ablation, transcatheter arterial chemoembolization (TACE), or yttrium-90 ( 90 Y) radioembolization .</p><p>Multidetector-row computed tomography (MDCT) has been widely used for assessing tumor response after therapy . To develop a common language and standardize the response evaluation, several criteria were developed, such as the World Health Organization (WHO) guidelines, the Response Evaluation Criteria in Solid Tumors (RECIST), and its more recent update, RECIST 1.1 . These guidelines require decrease of the tumor size as a marker for a positive response . Response to locoregional therapy, however, may not lead to a reduction in tumor volume . Indeed, with directed therapy, tumoral tissue may undergo necrosis, which may even lead to an increase in the size of the lesion . Therefore, the European Association for the Study of the Liver (EASL) has published a guideline recommending that the reduction in the amount of tumor viable tissue should be used to assess tumor response to localized treatment (where viable tissue means tumor regions that did not undergo necrosis) . Since then, the evaluation of tumor viable tissue has been increasingly used as a surrogate marker to assess response to locoregional therapies. The EASL guidelines recommend quantifying the amount of necrosis as a way to estimate the amount of viable tumor tissue. Most investigators have applied the two-dimensional (2D) measurements modified from WHO guidelines on a single axial plane to quantify necrosis . The modified RECIST proposed by the American Association for the Study of Liver Diseases uses the single longest axial diameter of the necrotic area to assess response to locoregional therapy, but it has not yet been widely validated; however, a new report suggests that modified RECIST may be superior to RECIST1.1 .</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="materials-and-methods-1"><span class="mr-2">Materials and methods</span><a href="#materials-and-methods-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="patients"><span class="mr-2">Patients</span><a href="#patients" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="90--y-radioembolization"><span class="mr-2">90 Y Radioembolization</span><a href="#90--y-radioembolization" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="computed-tomography-technique"><span class="mr-2">Computed Tomography Technique</span><a href="#computed-tomography-technique" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="lesion-selection-and-evaluation"><span class="mr-2">Lesion Selection and Evaluation</span><a href="#lesion-selection-and-evaluation" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="2d-measurement"><span class="mr-2">2D Measurement</span><a href="#2d-measurement" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/MDCTNecrosisQuantificationintheAssessmentofHepatocellularCarcinomaResponsetoYttrium90RadioembolizationTherapy/0_1s20S1076633211004326.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/MDCTNecrosisQuantificationintheAssessmentofHepatocellularCarcinomaResponsetoYttrium90RadioembolizationTherapy/0_1s20S1076633211004326.jpg" alt="Figure 1, A 52-year-old man with hepatocellular carcinoma located in the right lobe, treated with yttrium-90 radioembolization. The images show a follow-up multidetector computed tomography performed approximately 30 days after treatment, demonstrating the steps necessary for two-dimensional necrosis evaluation. The postcontrast late-arterial phase was used for the evaluation. (a) First step: measurement of the tumor cross-product in the axial slice where the tumor has the largest area, using the methodology described in the World Health Organization guideline. (b) Second step: measurement of the necrosis cross-product in the same slice as before, using the same methodology. The two-dimensional necrosis proportion is obtained by dividing the necrosis cross-product by the tumor cross-product." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>V=43πr3, V</p><p>=</p><p>4</p><p>3</p><p>π</p><p>r</p><p>3</p><p>,</p><p>and the area <em>A</em> of a circle of radius <em>r</em> is calculated by:</p><p>A=πr2 A</p><p>=</p><p>π</p><p>r</p><p>2</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Pv=VnVt=4/3πN34/3πT3=(NT)3 P</p><p>v</p><p>=</p><p>V</p><p>n</p><p>V</p><p>t</p><p>=</p><p>4</p><p>/</p><p>3</p><p>π</p><p>N</p><p>3</p><p>4</p><p>/</p><p>3</p><p>π</p><p>T</p><p>3</p><p>=</p><p>(</p><p>N</p><p>T</p><p>)</p><p>3</p><p>in which <em>Vn</em> = necrosis volume and <em>Vt</em> = tumor volume.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Pb=AnAt=πN2πT2=(NT)2 P</p><p>b</p><p>=</p><p>A</p><p>n</p><p>A</p><p>t</p><p>=</p><p>π</p><p>N</p><p>2</p><p>π</p><p>T</p><p>2</p><p>=</p><p>(</p><p>N</p><p>T</p><p>)</p><p>2</p><p>in which <em>Pb</em> = two-dimensional proportion, <em>An</em> = necrotic area, and <em>At</em> = tumor area.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>NT=Pb−−−√2 N</p><p>T</p><p>=</p><p>P</p><p>b</p><p>2</p><p>and substituting into the first equation we arrive at:</p><p>Pv=(NT)3=(Pb−−−√2)3 P</p><p>v</p><p>=</p><p>(</p><p>N</p><p>T</p><p>)</p><p>3</p><p>=</p><p>(</p><p>P</p><p>b</p><p>2</p><p>)</p><p>3</p><p>thus being able to convert 2D necrosis proportions to volumetric-equivalent necrosis proportions.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="volumetric-quantification"><span class="mr-2">Volumetric Quantification</span><a href="#volumetric-quantification" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/MDCTNecrosisQuantificationintheAssessmentofHepatocellularCarcinomaResponsetoYttrium90RadioembolizationTherapy/1_1s20S1076633211004326.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/MDCTNecrosisQuantificationintheAssessmentofHepatocellularCarcinomaResponsetoYttrium90RadioembolizationTherapy/1_1s20S1076633211004326.jpg" alt="Figure 2, A 52-year-old man with hepatocellular carcinoma treated with yttrium-90. Multidetector computed tomography volumetric evaluation of tumor necrosis proportion. (a) First step: semiautomated tumor segmentation ( white arrow ). The tumor borders are defined by the software and, if necessary, corrected by the user ( yellow lines ). (b) Second step: the attenuation threshold to define enhancement is determined by inserting circular regions of interest (ROIs) in the arterial phase image and it is coregistered with the unenhanced images. A total of 10 Hounsfield units (HU) is added to the mean attenuation values obtained by placing ROIs in the unenhanced images. (c) Third step: necrosis definition. After a HU threshold is entered by the user, every pixel within the segmented tumor with attenuation equal or lesser than it is shown in red ( white star ) and its volume is quantified by the software." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="statistical-analysis"><span class="mr-2">Statistical Analysis</span><a href="#statistical-analysis" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="results-1"><span class="mr-2">Results</span><a href="#results-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="interobserver-reproducibility"><span class="mr-2">Interobserver Reproducibility</span><a href="#interobserver-reproducibility" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Table 1</p><p>Parameters Used to Assess Reproducibility for Two Independent Observers Estimating the Proportion of Necrosis within a Tumor by Two Different Methods</p><p>Statistics Parameter Measurement Method Two-dimensional Measurements Volumetric Quantification Mean difference ± SD −0.03 ± 0.14 −0.08 ± 0.10 WSCV 43.8% 27.8% ICC 0.8454 0.9138 LCC 0.8407 0.9089</p><p>ICC, intraclass correlation coefficient; LCC, Lin’s concordance coefficient; WSCV, within-subject coefficient of variation.</p><p>Data pertain to two independent observers.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="assessment-of-agreement-between-methods"><span class="mr-2">Assessment of Agreement between Methods</span><a href="#assessment-of-agreement-between-methods" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/MDCTNecrosisQuantificationintheAssessmentofHepatocellularCarcinomaResponsetoYttrium90RadioembolizationTherapy/2_1s20S1076633211004326.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/MDCTNecrosisQuantificationintheAssessmentofHepatocellularCarcinomaResponsetoYttrium90RadioembolizationTherapy/2_1s20S1076633211004326.jpg" alt="Figure 3, Bland-Altman plot to show agreement between two-dimensional and volumetric methods of measuring tumor necrosis proportion." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="discussion"><span class="mr-2">Discussion</span><a href="#discussion" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/MDCTNecrosisQuantificationintheAssessmentofHepatocellularCarcinomaResponsetoYttrium90RadioembolizationTherapy/3_1s20S1076633211004326.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/MDCTNecrosisQuantificationintheAssessmentofHepatocellularCarcinomaResponsetoYttrium90RadioembolizationTherapy/3_1s20S1076633211004326.jpg" alt="Figure 4, Multidetector computed tomography of a 67-year-old man with hepatocellular carcinoma in the right lobe treated with yttrium-90 radioembolization. The necrotic component is underestimated on the axial image (a) when compared with the coronal image (b) because of the heterogeneous distribution of necrosis ( arrows )." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="references"><span class="mr-2">References</span><a href="#references" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><ul><li><p>1. Bruix J., Sherman M.: Management of hepatocellular carcinoma. Hepatology 2005; 42: pp. 1208-1236.</p><li><p>2. Salem R., Hunter R.D.: Yttrium-90 microspheres for the treatment of hepatocellular carcinoma: a review. Int J Radiat Oncol Biol Phys 2006; 66: pp. S83-S88.</p><li><p>3. Rhee T.K., Naik N.K., Deng J., et. al.: Tumor response after yttrium-90 radioembolization for hepatocellular carcinoma: comparison of diffusion-weighted functional MR imaging with anatomic MR imaging. J Vasc Interv Radiol 2008; 19: pp. 1180-1186.</p><li><p>4. Memon K., Kulik L., Lewandowski R.J., et. al.: Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology 2011; 141: pp. 526-535.</p><li><p>5. Keil S., Behrendt F.F., Stanzel S., et. al.: Semi-automated measurement of hyperdense, hypodense and heterogeneous hepatic metastasis on standard MDCT slices. Comparison of semi-automated and manual measurement of RECIST and WHO criteria. Eur Radiol 2008; 18: pp. 2456-2465.</p><li><p>6. Eisenhauer E.A., Therasse P., Bogaerts J., et. al.: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: pp. 228-247.</p><li><p>7. Nishino M., Jagannathan J.P., Ramaiya N.H., et. al.: Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know. AJR Am J Roentgenol 2010; 195: pp. 281-289.</p><li><p>8. Forner A., Ayuso C., Varela M., et. al.: Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?. Cancer 2009; 115: pp. 616-623.</p><li><p>9. Ibrahim S.M., Nikolaidis P., Miller F.H., et. al.: Radiologic findings following Y90 radioembolization for primary liver malignancies. Abdom Imaging 2009; 34: pp. 566-581.</p><li><p>10. Keppke A.L., Salem R., Reddy D., et. al.: Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres. AJR Am J Roentgenol 2007; 188: pp. 768-775.</p><li><p>11. Bruix J., Sherman M., Llovet J.M., et. al.: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: pp. 421-430.</p><li><p>12. Spira D., Fenchel M., Lauer U.M., et. al.: Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib. Acad Radiol 2011; 18: pp. 89-96.</p><li><p>13. Kuhnigk J.M., Dicken V., Bornemann L., et. al.: Morphological segmentation and partial volume analysis for volumetry of solid pulmonary lesions in thoracic CT scans. IEEE Trans Med Imaging 2006; 25: pp. 417-434.</p><li><p>14. Moltz J.H., Bornemann L., Kuhnigk J.M., et. al.: Advanced segmentation techniques for lung nodules, liver metastases, and enlarged lymph nodes in CT scans. IEEE J Sel Top Signal Process 2009; 3: pp. 122-134.</p><li><p>15. Bornemann L., Kuhnigk J.M., Dicken V., et. al.: Informatics in radiology (infoRAD): new tools for computer assistance in thoracic CT part 2. Therapy monitoring of pulmonary metastases. Radiographics 2005; 25: pp. 841-848.</p><li><p>16. Bornemann L., Dicken V., Kuhnigk J.M., et. al.: OncoTREAT: a software assistant for cancer therapy monitoring. Int J CARS 2007; 1: pp. 231-242.</p><li><p>17. Monsky W.L., Garza A.S., Kim I., et. al.: Treatment planning and volumetric response assessment for Yttrium-90 radioembolization: semiautomated determination of liver volume and volume of tumor necrosis in patients with hepatic malignancy. Cardiovasc Intervent Radiol 2011; 34: pp. 306-318.</p><li><p>18. Sato K.T., Lewandowski R.J., Mulcahy M.F., et. al.: Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres—safety, efficacy, and survival. Radiology 2008; 247: pp. 507-515.</p><li><p>19. Salem R., Thurston K.G.: Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations. J Vasc Interv Radiol 2006; 17: pp. 1251-1278.</p><li><p>20. Dawson P.: Multi-slice CT contrast enhancement regimens. Clin Radiol 2004; 59: pp. 1051-1060.</p><li><p>21. Laghi A.: Multidetector CT (64slices) of the liver: examination techniques. Eur Radiol 2007; 17: pp. 675-683.</p><li><p>22. Fleischmann D., Kamaya A.: Optimal vascular and parenchymal contrast enhancement: the current state of the art. Radiol Clin North Am 2009; 47: pp. 13-26.</p><li><p>23. Miller F.H., Butler R.S., Hoff F.L., et. al.: Using triphasic helical CT to detect focal hepatic lesions in patients with neoplasms. AJR Am J Roentgenol 1998; 171: pp. 643-649.</p><li><p>24. Lencioni R., Llovet J.M.: Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: pp. 52-60.</p><li><p>25. Miller A.B., Hoogstraten B., Staquet M., et. al.: Reporting results of cancer treatment. Cancer 1981; 47: pp. 207-214.</p><li><p>26. Suzuki C., Jacobsson H., Hatschek T., et. al.: Radiologic measurements of tumor response to treatment: practical approaches and limitations. Radiographics 2008; 28: pp. 329-344.</p><li><p>27. Bosniak M.A.: The current radiological approach to renal cysts. Radiology 1986; 158: pp. 1-10.</p><li><p>28. Miller F.H., Keppke A.L., Reddy D., et. al.: Response of liver metastases after treatment with yttrium-90 microspheres: role of size, necrosis, and PET. AJR Am J Roentgenol 2007; 188: pp. 776-783.</p><li><p>29. Lin L.I.: A concordance correlation coefficient to evaluate reproducibility. Biometrics 1989; 45: pp. 255-268.</p><li><p>30. Mantatzis M., Kakolyris S., Amarantidis K., et. al.: Treatment response classification of liver metastatic disease evaluated on imaging. Are RECIST unidimensional measurements accurate?. Eur Radiol 2009; 19: pp. 1809-1816.</p><li><p>31. Therasse P., Arbuck S.G., Eisenhauer E.A., et. al.: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: pp. 205-216.</p><li><p>32. Tochetto S.M., Rezai P., Rezvani M., et. al.: Does multidetector CT attenuation change in colon cancer liver metastases treated with 90Y help predict metabolic activity at FDG PET?. Radiology 2010; 255: pp. 164-172.</p><li><p>33. Yaghmai V., Miller F.H., Rezai P., et. al.: Response to treatment series: part 2, tumor response assessment—using new and conventional criteria. AJR Am J Roentgenol 2011; 197: pp. 18-27.</p><li><p>34. Gillmore R., Stuart S., Kirkwood A., et. al.: EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolisation. J Hepatol 2011; April 15. [Epub ahead of print]</p><li><p>35. Duke E., Deng J., Ibrahim S.M., et. al.: Agreement between competing imaging measures of response of hepatocellular carcinoma to yttrium-90 radioembolization. J Vasc Interv Radiol 2010; 21: pp. 515-521.</p><li><p>36. Llovet J.M., Di Bisceglie A.M., Bruix J., et. al.: Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: pp. 698-711.</p><li><p>37. Riaz A., Memon K., Miller F.H., et. al.: Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. J Hepatol 2011; 54: pp. 695-704.</p><li><p>38. Jaffe C.C.: Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol 2006; 24: pp. 3245-3251.</p><li><p>39. Lu D.S., Yu N.C., Raman S.S., et. al.: Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. Radiology 2005; 234: pp. 954-960.</p><li><p>40. Herber S., Biesterfeld S., Franz U., et. al.: Correlation of multislice CT and histomorphology in HCC following TACE: predictors of outcome. Cardiovasc Intervent Radiol 2008; 31: pp. 768-777.</p><li><p>41. Riaz A., Miller F.H., Kulik L.M., et. al.: Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA 2010; 303: pp. 1062-1069.</p></ul></div><div class="post-tail-wrapper text-muted"><div class="post-meta mb-3"> <i class="far fa-folder-open fa-fw mr-1"></i> <a href='/categories/academic-radiology/'>Academic Radiology</a>, <a href='/categories/volume-19/'>Volume 19</a>, <a href='/categories/issue-1/'>Issue 1</a></div><div class="post-tags"> <i class="fa fa-tags fa-fw mr-1"></i> <a href="/tags/journals/" class="post-tag no-text-decoration" >Journals</a> <a href="/tags/general-radiology/" class="post-tag no-text-decoration" >General Radiology</a></div><div class="post-tail-bottom d-flex justify-content-between align-items-center mt-3 pt-5 pb-2"><div class="license-wrapper"> This post is licensed under <a href="https://creativecommons.org/licenses/by/4.0/"> CC BY 4.0 </a> by the author.</div><div class="share-wrapper"> <span class="share-label text-muted mr-1">Share</span> <span class="share-icons"> <a href="https://twitter.com/intent/tweet?text=MDCT%20Necrosis%20Quantification%20in%20the%20Assessment%20of%20Hepatocellular%20Carcinoma%20Response%20to%20Yttrium%2090%20Radioembolization%20Therapy%20-%20Radiology%20Tree&url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fmdct-necrosis-quantification-in-the-assessment-of-hepatocellular-carcinoma-response-to-yttrium-90-ra%2F" data-toggle="tooltip" data-placement="top" title="Twitter" target="_blank" rel="noopener" aria-label="Twitter"> <i class="fa-fw fab fa-twitter"></i> </a> <a href="https://www.facebook.com/sharer/sharer.php?title=MDCT%20Necrosis%20Quantification%20in%20the%20Assessment%20of%20Hepatocellular%20Carcinoma%20Response%20to%20Yttrium%2090%20Radioembolization%20Therapy%20-%20Radiology%20Tree&u=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fmdct-necrosis-quantification-in-the-assessment-of-hepatocellular-carcinoma-response-to-yttrium-90-ra%2F" data-toggle="tooltip" data-placement="top" title="Facebook" target="_blank" rel="noopener" aria-label="Facebook"> <i class="fa-fw fab fa-facebook-square"></i> </a> <a href="https://t.me/share/url?url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fmdct-necrosis-quantification-in-the-assessment-of-hepatocellular-carcinoma-response-to-yttrium-90-ra%2F&text=MDCT%20Necrosis%20Quantification%20in%20the%20Assessment%20of%20Hepatocellular%20Carcinoma%20Response%20to%20Yttrium%2090%20Radioembolization%20Therapy%20-%20Radiology%20Tree" data-toggle="tooltip" data-placement="top" title="Telegram" target="_blank" rel="noopener" aria-label="Telegram"> <i class="fa-fw fab fa-telegram"></i> </a> <i id="copy-link" class="fa-fw fas fa-link small" data-toggle="tooltip" data-placement="top" title="Copy link" data-title-succeed="Link copied successfully!"> </i> </span></div></div></div></div></div><div id="panel-wrapper" class="col-xl-3 pl-2 text-muted"><div class="access"><div id="access-lastmod" class="post"><div class="panel-heading">Recently Updated</div><ul class="post-content pl-0 pb-1 ml-1 mt-2"><li><a href="/posts/neurometabolites-alteration-in-the-acute-phase-of-mild-traumatic-brain-injury-mtbi/">Neurometabolites Alteration in the Acute Phase of Mild Traumatic Brain Injury (mTBI)</a><li><a href="/posts/reinforcing-the-importance-and-feasibility-of-implementing-a-low-dose-protocol-for-ct-guided-biopsie/">Reinforcing the Importance and Feasibility of Implementing a Low-dose Protocol for CT-guided Biopsies</a><li><a href="/posts/rethinking-the-pgy-1-basic-clinical-year/">Rethinking the PGY-1 Basic Clinical Year</a><li><a href="/posts/single-injection-dual-phase-cone-beam-ct-dp-cbct-vascular-anatomy-assessment-and-occult-nodule-det/">Single Injection Dual-Phase Cone Beam CT (DP-CBCT) Vascular Anatomy Assessment and Occult Nodule Detection; Have We Reached the Focus?</a><li><a href="/posts/the-yellow-scale-is-superior-to-the-gray-scale-for-detecting-acute-ischemic-stroke-on-a-monitor-disp/">The Yellow Scale Is Superior to the Gray Scale for Detecting Acute Ischemic Stroke on a Monitor Display in Computed Tomography</a></ul></div><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="toc-wrapper" class="pl-0 pr-4 mb-5"><div class="panel-heading pl-3 pt-2 mb-2">Contents</div><nav id="toc"></nav></div><script src="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.js"></script></div></div><div class="row"><div id="tail-wrapper" class="col-12 col-lg-11 col-xl-9 pl-3 pr-3 pr-xl-4 mt-5"><div id="related-posts" class="mb-2 mb-sm-4"><h3 class="pt-2 mb-4 ml-1" data-toc-skip>Further Reading</h3><div class="card-deck mb-4"><div class="card"> <a href="/posts/a-semi-automatic-algorithm-for-determining-the-demyelination-load-in-metachromatic-leukodystrophy/"><div class="card-body"> <em class="small" data-ts="1325350800" data-df="ll" > Dec 31, 2011 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>A Semi-Automatic Algorithm for Determining the Demyelination Load in Metachromatic Leukodystrophy</h3><div class="text-muted small"><p> Rationale and Objectives Metachromatic leukodystrophy is a lysosomal storage disorder leading to progressive demyelination of brain white matter. This is sensitively detected using magnetic resona...</p></div></div></a></div><div class="card"> <a href="/posts/breast-cancer-risk-assessment-in-64-659-women-at-a-single-high-volume-mammography-clinic/"><div class="card-body"> <em class="small" data-ts="1325350800" data-df="ll" > Dec 31, 2011 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Breast Cancer Risk Assessment in 64,659 Women at a Single High-Volume Mammography Clinic</h3><div class="text-muted small"><p> Rationale and Objectives In 2007, the American Cancer Society (ACS) recommended that women at elevated risk of breast cancer be screened with breast magnetic resonance imaging (MRI) as an adjunct ...</p></div></div></a></div><div class="card"> <a href="/posts/can-whole-body-low-dose-multidetector-ct-exclude-the-presence-of-myeloma-bone-disease-in-patients-wi/"><div class="card-body"> <em class="small" data-ts="1325350800" data-df="ll" > Dec 31, 2011 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Can Whole-body Low-dose Multidetector CT Exclude the Presence of Myeloma Bone Disease in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS)?</h3><div class="text-muted small"><p> Rationale and Objectives To determine the benefit of using whole-body low-dose computed tomography (WBLD-CT) in patients with monoclonal gammopathy of undetermined significance (MGUS) for exclusio...</p></div></div></a></div></div></div><div class="post-navigation d-flex justify-content-between"> <a href="/posts/low-grade-bone-lesions-in-survivors-of-childhood-medulloblastoma-primitive-neuroectodermal-tumor/" class="btn btn-outline-primary" prompt="Older"><p>Low-grade Bone Lesions in Survivors of Childhood Medulloblastoma/Primitive Neuroectodermal Tumor</p></a> <a href="/posts/parametric-histogram-analysis-of-dynamic-contrast-enhanced-mri-in-multiple-myeloma/" class="btn btn-outline-primary" prompt="Newer"><p>Parametric Histogram Analysis of Dynamic Contrast-enhanced MRI in Multiple Myeloma</p></a></div></div></div></div><div id="search-result-wrapper" class="d-flex justify-content-center unloaded"><div class="col-12 col-sm-11 post-content"><div id="search-hints"><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="search-results" class="d-flex flex-wrap justify-content-center text-muted mt-3"></div></div></div></div><footer><div class="container pl-lg-4 pr-lg-4"><div class="d-flex justify-content-between align-items-center text-muted ml-md-3 mr-md-3"><div class="footer-left"><p class="mb-0"> © 2023 <a href="https://twitter.com/username">Clinical Team</a>. <span data-toggle="tooltip" data-placement="top" title="Except where otherwise noted, the blog posts on this site are licensed under the Creative Commons Attribution 4.0 International (CC BY 4.0) License by the author.">Some rights reserved.</span></p></div><div class="footer-right"><p class="mb-0">Using the <a href="https://jekyllrb.com" target="_blank" rel="noopener">Jekyll</a> theme <a href="https://github.com/cotes2020/jekyll-theme-chirpy" target="_blank" rel="noopener">Chirpy</a>.</p></div></div></div></footer><div id="mask"></div><a id="back-to-top" href="#" aria-label="back-to-top" class="btn btn-lg btn-box-shadow" role="button"> <i class="fas fa-angle-up"></i> </a><div id="notification" class="toast" role="alert" aria-live="assertive" aria-atomic="true" data-animation="true" data-autohide="false"><div class="toast-header"> <button type="button" class="ml-2 ml-auto close" data-dismiss="toast" aria-label="Close"> <span aria-hidden="true">&times;</span> </button></div><div class="toast-body text-center pt-0"><p class="pl-2 pr-2 mb-3">A new version of content is available.</p><button type="button" class="btn btn-primary" aria-label="Update"> Update </button></div></div><script src="https://cdn.jsdelivr.net/npm/simple-jekyll-search@1.10.0/dest/simple-jekyll-search.min.js"></script> <script> SimpleJekyllSearch({ searchInput: document.getElementById('search-input'), resultsContainer: document.getElementById('search-results'), json: '/assets/js/data/search.json', searchResultTemplate: '<div class="pl-1 pr-1 pl-sm-2 pr-sm-2 pl-lg-4 pr-lg-4 pl-xl-0 pr-xl-0"> <a href="{url}">{title}</a><div class="post-meta d-flex flex-column flex-sm-row text-muted mt-1 mb-1"> {categories} {tags}</div><p>{snippet}</p></div>', noResultsText: '<p class="mt-5">Oops! No results found.</p>', templateMiddleware: function(prop, value, template) { if (prop === 'categories') { if (value === '') { return `${value}`; } else { return `<div class="mr-sm-4"><i class="far fa-folder fa-fw"></i>${value}</div>`; } } if (prop === 'tags') { if (value === '') { return `${value}`; } else { return `<div><i class="fa fa-tag fa-fw"></i>${value}</div>`; } } } }); </script> <script src="https://cdn.jsdelivr.net/combine/npm/magnific-popup@1.1.0/dist/jquery.magnific-popup.min.js,npm/lazysizes@5.3.2/lazysizes.min.js,npm/clipboard@2.0.11/dist/clipboard.min.js"></script> <script src="https://cdn.jsdelivr.net/combine/npm/dayjs@1.11.6/dayjs.min.js,npm/dayjs@1.11.6/locale/en.min.js,npm/dayjs@1.11.6/plugin/relativeTime.min.js,npm/dayjs@1.11.6/plugin/localizedFormat.min.js"></script> <script defer src="/assets/js/dist/post.min.js"></script> <script src="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/js/bootstrap.bundle.min.js"></script> <script defer src="/app.js"></script> <script defer src="https://www.googletagmanager.com/gtag/js?id=G-L66SLQK23K"></script> <script> document.addEventListener("DOMContentLoaded", function(event) { window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-L66SLQK23K'); }); </script>
